Acuity 200 (Fluoroxyfocon A) contact lens
DeviceDaily wear rigid gas permeable contact lens
NCT Number: NCT03971227
The objective of this clinical investigation is to collect valid scientific safety and effectiveness data on the Acuity 200 (fluoroxyfocon A) Rigid Gas Permeable Contact Lens, manufactured from a newly developed rigid gas permeable material that is highly permeable to oxygen. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a 510(k) premarket notification.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Ala Mona Advanced Eye Clinic, Honolulu, Hawaii, United States
This is an open-label, multi-center, randomized concurrent-control study with the treatment duration of 90 days. Subjects will be recruited into the study based upon the inclusion and exclusion criteria provided. Eligible subjects will be examined for baseline evaluation and lens fitting. Up to sixty (60) subjects will wear the test contact lenses for daily wear and up to twenty-eight (28) subjects will wear the control contact lenses. The subjects will attend seven scheduled study visits and will undergo standard ophthalmic evaluation for contact lens care. The subjects will be followed for a period of three months (90 days) following dispensing of the Test and Control Device.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Prior to being considered eligible to participate in this study, each subject MUST:
Exclusion criteria
Subjects may not be enrolled into the study if ANY of the following apply:
To be eligible to be randomized for study product trial a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present. To be eligible for lens dispensing, the subject's study device contact lens visual acuity must be equal to or better than 0.20 log MAR (20/32 Snellen) in each eye
-
Daily wear rigid gas permeable contact lens
Daily wear rigid gas permeable contact lens
Time frame: 90 days
Comparison of the corrected visual acuity (logMAR) between the Test and Control lens. The working hypothesis is that the visual acuity results will be substantially equivalent between the Test and the Control lenses.
Time frame: 90 days
Comparison of slit lamp exam findings (scored from 0-4) between Test and Control arms. The working hypothesis is that the findings will be substantially equivalent between the Test and the Control lenses.
Time frame: 90 days
Comparison of the number of device related adverse events in the Test and Control arms. The working hypothesis is that the number of adverse events will be substantially equivalent between the Test and the Control lenses.
Time frame: 90 days
Comparison of subjective symptoms (scored from 0-5) between Test and Control arms. The working hypothesis is that the symptoms will be substantially equivalent between the Test and the Control lenses.
Acuity Polymers, Inc.
Industry
Clinical Evaluation of Safety and Effectiveness for the Acuity 200 (Fluoroxyfocon A) Rigid Gas Permeable Contact Lens
Acronym: Acuity 200
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07614113
Eye Diseases, Myopia
Faisalābad, Punjab Province, Pakistan
View Trial DetailsNCT06716372
Eye Diseases, Myopia
Taipei, Taiwan
View Trial DetailsNCT06716385
Eye Diseases, Myopia
Taipei, Taiwan
View Trial DetailsNCT06884202
Eye Diseases, Myopia
Los Angeles, California, United States
View Trial Details